BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9421310)

  • 1. Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria.
    Kato N; Kato H; Tanaka-Bandoh K; Watanabe K; Ueno K
    J Antimicrob Chemother; 1997 Nov; 40(5):631-7. PubMed ID: 9421310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
    Hosaka M; Kinoshita S; Toyama A; Otsuki M; Nishino T
    J Antimicrob Chemother; 1995 Aug; 36(2):293-301. PubMed ID: 8522459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
    Nord CE
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
    Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
    Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D
    J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of Bay Y3118 against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
    King A; Bethune L; Phillips I
    J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
    Wexler HM; Molitoris E; Reeves D; Finegold SM
    J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
    Aldridge KE
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.
    Wakabayashi E; Mitsuhashi S
    Antimicrob Agents Chemother; 1994 Mar; 38(3):594-601. PubMed ID: 8203860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
    Goldstein EJ
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S377-81. PubMed ID: 8324151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of three of the newer quinolones against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.
    Ackermann G; Schaumann R; Pless B; Claros MC; Goldstein EJ; Rodloff AC
    Eur J Clin Microbiol Infect Dis; 2000 Mar; 19(3):228-32. PubMed ID: 10795599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of DU-6859a against anaerobic bacteria.
    Wexler HM; Molitoris E; Reeves D; Finegold SM
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.
    Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2459-62. PubMed ID: 9736586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of anaerobic bacteria to PD 131628.
    Nord CE; Hagelbäck A
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):68-71. PubMed ID: 1314176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.
    Kato N; Kato H; Tanaka-Bando K; Watanabe K; Ueno K
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S31-5. PubMed ID: 8953104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.